May 8, 2025

Edgewise boosted 1Q balance sheet with stock sale

Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, ended the first quarter of 2025 with a proforma balance of $624.4 million, thanks in part to a $200 million stock sale in April.

Related Posts

A Maryland native, Lucas has worked at news agencies from Wyoming to South Carolina before putting roots down in Colorado.
Sign up for BizWest Daily Alerts
Closing in 8 seconds...